carboxypeptidase b2


Summary: A carboxypeptidase that removes C-terminal lysine or arginine from peptides and proteins. Carboxypeptidase B2 (CPB2) is released into the circulation as a proenzyme which is activated by the THROMBIN-THROMBOMODULIN complex. Activated CPB2 is involved in modulating a variety of processes by cleaving and inactivating various circulating proteins and peptides that are its substrates including FIBRIN; KININS; and ANAPHYLATOXINS.

Top Publications

  1. Caulfield A, Lathem W. Substrates of the plasminogen activator protease of Yersinia pestis. Adv Exp Med Biol. 2012;954:253-60 pubmed publisher
  2. Bridge K, Revill C, Macrae F, Bailey M, Yuldasheva N, Wheatcroft S, et al. Inhibition of plasmin-mediated TAFI activation may affect development but not progression of abdominal aortic aneurysms. PLoS ONE. 2017;12:e0177117 pubmed publisher
    ..Late treatment with a TAFI inhibitor does not prevent AAA progression. These data may indicate a role for inhibition of plasmin-mediated TAFI activation in the early stages of AAA development, but not in its progression. ..
  3. Zwingerman N, Medina Rivera A, Kassam I, Wilson M, Morange P, Tregouet D, et al. Sex-specific effect of CPB2 Ala147Thr but not Thr325Ile variants on the risk of venous thrombosis: A comprehensive meta-analysis. PLoS ONE. 2017;12:e0177768 pubmed publisher
    Thrombin activatable fibrinolysis inhibitor (TAFI), encoded by the Carboxypeptidase B2 gene (CPB2), is an inhibitor of fibrinolysis and plays a role in the pathogenesis of venous thrombosis...